Oncotarget

Research Papers:

The prognostic and predictive value of the lymphocyte to monocyte ratio in luminal-type breast cancer patients treated with CEF chemotherapy

Hongfei Ji, Qijia Xuan, Caichuan Yan, Tao Liu, Abiyasi Nanding and Qingyuan Zhang _

PDF  |  HTML  |  Order a Reprint

Oncotarget. 2016; 7:34881-34889. https://doi.org/10.18632/oncotarget.8993

Metrics: PDF 655 views  |   HTML 718 views  |   ?  


Abstract

Hongfei Ji1,3,*, Qijia Xuan2,*, Caichuan Yan1,3, Tao Liu2, Abiyasi Nanding4, Qingyuan Zhang1,2,3

1Department of Cancer Molecular and Biology, Cancer Institute, Harbin Medical University, Harbin, China

2Department of Medical Oncology, Tumor Hospital of Harbin Medical University, Harbin, China

3Department of Cancer Molecular and Biology, Heilongjiang Academy of Medical Sciences, Harbin, China

4Department of Pathology, Tumor Hospital of Harbin Medical University, Harbin, China

*These authors have contributed equally to this work

Correspondence to:

Qingyuan Zhang, e-mail: zqyxsci@126.com

Keywords: breast cancer, lymphocyte-to-monocyte ratio, 5-fluorouracil, prognostic factor

Received: December 03, 2015     Accepted: April 11, 2016     Published: April 26, 2016

ABSTRACT

Several reports have suggested that peripheral blood-based parameters are associated with host immunity response, which is an essential component of the pathogenesis and progression of cancer. The purpose of the present study was to identify the prognostic significance of various peripheral blood-based biomarkers and to determine the optimal cut-off value suitable for luminal breast cancer patients. We found that lymphocyte-to-monocyte ratio (LMR) was significant prognostic predictors. And the patients with a CEF regimen and LMR ratio ≥ 5.2 gained a good prognosis. This study suggested that the LMR could be regarded as an independent prognostic factor in luminal breast cancer patients. The elevated LMR level also had enhanced 5-fluorouracil sensitivity in luminal breast cancer patients.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 8993